ArticleBMC infectious diseases2025
Antimicrobial resistance trends of Escherichia coli and Staphylococcus aureus isolated from clinical blood cultures in Namibia: a nine-year (2011-2019) retrospective study.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDue to inadequate data on the antimicrobial resistance situation among the two predominant bacteremia-causing pathogens, the objective was to analyze the nine-year antimicrobial resistance trends of Escherichia coli (E. coli) and Staphylococcus aureus (S. aureus) from blood cultures.
methodsA nine-year countrywide register data (2011–2019) covering all microbiological specimen tests performed at the Namibia Institute of Pathology (NIP) were analyzed. Antimicrobial susceptibility testing (AST) was performed by disk diffusion and VITEK-2, along with Quality Control parallels to validate AST results. This was interpreted in accordance with the prevailing CLSI breakpoints. Data analysis included descriptive statistics and chi-square, Multiple Antibiotic Resistance (MAR) Index and Mann-Kendall trend tests (α = 0.05).
resultsThe original findings comprised 30,266 bacterial organisms isolated from 37,765 blood cultures. After adjusting for putative contaminants, the Gram-negative bacterial species (GNB) group comprised most of the major findings, including E. coli (15.2%), K. pneumoniae (13.2%), S. enterica (3.2%), and P. aeruginosa (2.8%). S. aureus (15.3%) and E. faecalis (6.5%) comprised the majority of gram-positive bacterial (GPB) organisms. E. coli and S. aureus were commonly isolated from the 15–59 and 0–4 age groups, respectively. Significant upward trends (for amoxicillin-clavulanate and 3rd generation cephalosporins) and downward trends (oxacillin and gentamicin) were found. In 2019, the following resistance to E. coli were observed: ceftriaxone (37%), ciprofloxacin (29.4%), gentamicin (18.8%), and meropenem (0.9%). In 2019, S. aureus resistance to oxacillin was 18.8%. The proportions of ESBLs increased from 22.1% (n = 79) to 42% (n = 116) (ss:1.75, p = 0.03). Whilst methicillin-resistant S. aureus (MRSA) reduced from 47.2% to 18.8% in 2019 (ss: −2.05, p = 0.03). The proportion of multi-drug resistant E. coli increased to 47.8% (p < 0.01), whilst extensive-drug resistant E. coli decreased to 3% (p = 0.04) and no potential pan-drug resistant organisms were found.
conclusionsTo our knowledge, this is the first study to provide a 9-year insight into the trends of antimicrobial resistance in clinical blood culture isolates in Namibia. ESBLs showed an increasing trend, whilst MRSAs declined due to potential improvements in infection prevention & control (IPC) and antimicrobial stewardship. Resistance levels of above 20% to critical antimicrobials (i.e. amoxicillin-clavulanate, ceftriaxone, ciprofloxacin, and erythromycin) is worrying for the management of bloodstream infections caused by ESBLs or MRSAs. Overall, this study serves as a baseline for future surveillance work and highlights the continuous need for AST-guided therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.